Pricing Log in Create free account

C4 Therapeutics, Inc. (CCCC) vs Editas Medicine, Inc. (EDIT)

C4 Therapeutics, Inc. and Editas Medicine, Inc. are both Biotechnology companies. C4 Therapeutics, Inc. and Editas Medicine, Inc. are of similar size ($399.3M and $394.9M). Editas Medicine, Inc. grew revenue faster over the last twelve months: 20.8% against 2.33%. Editas Medicine, Inc. has the higher net margin (−157.3% vs −289.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Editas Medicine, Inc. leads on 8 and C4 Therapeutics, Inc. on 7.

Valuation

Metric CCCC EDIT Biotechnology median
P/E n/m n/m 10.64
P/S 11.86 6.60 9.59
P/B 1.68 2.95 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 5.16 2.79 9.45
Earnings yield (31.45%) (28.85%) (34.69%)
Free cash flow yield (20.55%) (38.78%) (24.02%)

Profitability

Metric CCCC EDIT Biotechnology median
Gross margin 100.00% 100.00% 65.59%
Operating margin (318.97%) (161.39%) 0.00%
Net margin (289.44%) (157.32%) 0.00%
Free cash flow margin (243.71%) (255.88%) 0.00%
Return on equity (48.14%) (118.82%) (51.96%)
Return on assets (30.92%) (33.02%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CCCC EDIT Biotechnology median
Revenue growth (TTM) 2.33% 20.83% 4.59%
EPS growth (last fiscal year) 16.45% 37.50% 29.88%
Revenue growth, 5-year CAGR 1.61% (14.89%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CCCC EDIT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.45 3.19 4.86
Net debt to EBITDA 2.14 0.94 1.01

Dividend

Metric CCCC EDIT Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric CCCC EDIT Biotechnology median
Market cap 394.91m 399.31m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack